Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNK2 | Q07912 | 11/20 | 0.69 |
| ▸ | ABL1 | P00519 | 2/20 | 0.61 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | RET | P07949 | 3/20 | 0.48 |
| ▸ | KDR | P35968 | 3/20 | 0.48 |
| ▸ | BTK | Q06187 | 4/20 | 0.47 |
| ▸ | EGFR | P00533 | 2/20 | 0.46 |
| ▸ | TEC | P42680 | 2/20 | 0.46 |
| ▸ | TXK | P42681 | 2/20 | 0.46 |
| ▸ | BMX | P51813 | 2/20 | 0.46 |
| ▸ | ITK | Q08881 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12437034 | 0.82 | SRC (0.75) | TNK2ABL1SRCRETKDR | |
| SCHEMBL29390333 | 0.82 | SRC (0.75) | TNK2ABL1SRCRETKDR | |
| SCHEMBL1131713 | 0.82 | TNK2 (1.00) | TNK2BTK | |
| SCHEMBL18966402 | 0.81 | TNK2 (0.61) | TNK2ABL1SRCRETKDR | |
| SCHEMBL30493814 | 0.80 | TNK2 (0.60) | TNK2ABL1SRCRETKDR | |
| SCHEMBL14574763 | 0.78 | SRC (0.69) | TNK2ABL1SRCRETKDR | |
| SCHEMBL29390821 | 0.78 | SRC (0.69) | TNK2ABL1SRCRETKDR | |
| SCHEMBL31244390 | 0.77 | ABL1 (0.58) | TNK2ABL1SRCRETKDR | |
| SCHEMBL12436430 | 0.77 | SRC (0.70) | TNK2ABL1SRCRETKDR | |
| SCHEMBL18966606 | 0.77 | ERN1 (0.61) | TNK2ABL1SRCBTKEGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-9822120-B2 | Protein kinase inhibitors | PHARMASCIENCE INC. (CA) | 2017-11-21 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| US-20160280711-A1 | Protein Kinase Inhibitors | PHARMASCIENCE INC. (CA) | 2016-09-29 | — | — | US | disclosed |
| WO-2015074138-A1 | PROTEIN KINASE INHIBITORS | PHARMASCIENCE INC. (CA) | 2015-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160280711-A1 | Protein Kinase Inhibitors | TEC, LCK, SRC | TNK2 43/4885ABL1 16/4885SRC 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.